Artelo Biosciences (NASDAQ:ARTL) Posts Earnings Results, Misses Estimates By $0.04 EPS

Artelo Biosciences (NASDAQ:ARTL) announced its quarterly earnings results on Wednesday. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.04), MarketWatch Earnings reports.

ARTL traded down $0.04 during midday trading on Friday, hitting $0.97. The company’s stock had a trading volume of 33,614 shares, compared to its average volume of 5,222,977. The firm has a market cap of $14.63 million, a P/E ratio of -0.79 and a beta of 2.52. The firm has a 50-day moving average price of $0.71 and a two-hundred day moving average price of $0.85. Artelo Biosciences has a 52-week low of $0.45 and a 52-week high of $4.42.

Separately, Maxim Group upgraded Artelo Biosciences from a “hold” rating to a “buy” rating in a research report on Thursday, January 7th.

About Artelo Biosciences

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1 clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD.

See Also: Certificate of Deposit (CD)

Earnings History for Artelo Biosciences (NASDAQ:ARTL)

Receive News & Ratings for Artelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artelo Biosciences and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit